• Explore /
  • Poster
  • / Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.

Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.

Abstract Poster

Authors

Yada Kanjanapan

Yada Kanjanapan

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Yada Kanjanapan , Stephanie Lheureux , Taymaa May , Michelle K. Wilson , Marcus Bernardini , Patricia Ann Shaw , Ignace Vergote , James D. Brenton , Diane M. Provencher , Iain A. McNeish , Prafull Ghatage , Jonathan A. Ledermann , Nicoletta Colombo , Charlie Gourley , Johanne Weberpals , Janelle Ramsahai , Nicole Ricker , Sarah Accardi , Lisa Wang , Amit M. Oza

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02489006

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS5608)

DOI

10.1200/JCO.2017.35.15_suppl.TPS5608

Abstract #

TPS5608

Poster Bd #

426a

Abstract Disclosures

Similar Posters

First Author: Elias Chandran

Poster

2023 ASCO Annual Meeting

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).

First Author: June Evelyn Jeon

First Author: Kamal Kant Kant Sahu

First Author: Severine Guiu Lahaye